Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BGB-R046 + tislelizumab
- Development stage
- Unknown
- Lead developer
- BeiGene
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
BGB-R046 + tislelizumab is a combination investigational oncology therapy consisting of **BGB-R046**, a protease-activated **IL-15 pro-drug** (cytokine therapy) designed to deliver localized immune stimulation within the tumor microenvironment, and **tislelizumab** (BGB-A317), a humanized monoclonal antibody targeting **programmed cell death protein 1 (PD-1)**, functioning as an immune checkpoint inhibitor. BGB-R046 is engineered to remain inactive in circulation and be activated by tumor-associated proteases, releasing IL-15Rα-sushi-IL-15 (superagonist) at the tumor site, enhancing **natural killer (NK) cell** and **CD8+ T-cell** expansion. The combination aims to augment anti-tumor immunity while mitigating systemic toxicity of IL-15. Developed for advanced or metastatic immune-sensitive solid tumors, the combination is under investigation in a first-in-human, phase 1 clinical trial[1][3][4][5].
- Other names
- BGB-R046 + tislelizumab
02
Targets
IL2RB (IL-2 receptor beta chain)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on BGB-R046 + tislelizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BGB-R046 + tislelizumab.